
MoonLake Immunotherapeutics Investor Relations Material
Latest events

CMD 2024
MoonLake Immunotherapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies
Latest reports from MoonLake Immunotherapeutics
Access all reports
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company, focusing on the development of innovative therapies for inflammatory diseases. The company is advancing Sonelokimab, a novel investigational Nanobody, to address conditions such as hidradenitis suppurativa, psoriatic arthritis, ankylosing spondylitis, and axial spondyloarthritis. MoonLake Immunotherapeutics aims to leverage the therapeutic potential of Sonelokimab to meet significant unmet medical needs in the treatment of these diseases. MoonLake Immunotherapeutics is headquartered in Zug, Switzerland, and its shares are listed on the NASDAQ.
Key slides for MoonLake Immunotherapeutics


R&D Day 2024
MoonLake Immunotherapeutics


R&D Day 2024
MoonLake Immunotherapeutics
Latest articles
)
Robert G. Hagstrom: Darwinian Investing and Multidisciplinary Wisdom
Robert G. Hagstrom, author of The Warren Buffett Way, explores how interdisciplinary thinking shapes his investing, from Adler's reading to Darwinian markets.
7 Feb 2025
)
Quartr Brings Stories Behind the Numbers to Light
Quartr simplifies access to IR material and puts qualitative insights and company narratives front and center.
3 Feb 2025
)
The Evolution of the IRO Role: Staying Informed and Strategic With Quartr Pro
Staying informed is critical for IROs. Quartr Pro simplifies gathering market insights and narrative positioning with unprecedented speed and precision.
3 Feb 2025
Ticker symbol
MLTX
Country
🇺🇸 United States